P/E ratio for Trevena (TRVN)
P/E ratio as of April 2024 (TTM): -0.0817
According to Trevena's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0816964. At the end of 2022 the company had a P/E ratio of -0.1852.
P/E ratio history for Trevena from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1852 | -90.15% |
| 2021 | -1.88 | -78.91% |
| 2020 | -8.92 | 186.27% |
| 2019 | -3.11 | 211.48% |
| 2018 | -1.00 | -24.38% |
| 2017 | -1.32 | -55.92% |
| 2016 | -3.00 | -67.14% |
| 2015 | -9.13 | 214.53% |
| 2014 | -2.90 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 18.6 | -22,829.15% | 🇺🇸 USA |
 Merck MRK | 68.7 | -84,245.94% | 🇺🇸 USA |
 Flexion Therapeutics
FLXN | N/A | N/A | 🇺🇸 USA |
 Cytokinetics
CYTK | -11.8 | 14,313.12% | 🇺🇸 USA |
 AcelRx Pharmaceuticals
ACRX | -0.2783 | 240.67% | 🇺🇸 USA |
 Cara Therapeutics
CARA | -0.3350 | 309.99% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.